Protavio’s co-founder and National Technical University of Athens Professor, Dr. Leonidas Alexopoulos, took part in the recently concluded 9th Annual Conference of the Hellenic Cancer Federation (ELLOK). The event, which took place from February 3 to 5, 2025, in Athens, Greece, was organized around the theme “The Person at the Center: from Theory to Practice”, marking World Cancer Day (February 4). It brought together key government officials, distinguished researchers, healthcare professionals, industry experts, and patient advocacy representatives from across Greece and Europe, to discuss key health policy issues and developments that shape the quality of cancer prevention, early detection, care and treatment.
Dr. Alexopoulos spoke during Session 5, titled “The digital era as a catalyst for supporting cancer patients”, where he underscored the critical need to translate cutting-edge research into practical diagnostic solutions, a mission Protavio actively pursues through its multiplex proteomics approaches and advanced technology platforms. He highlighted that cancer early detection stands at a pivotal crossroads, where scientific breakthroughs and digital innovations can converge to deliver significant benefits for patients. By bridging academic discoveries with real-world diagnostics, clinicians can detect cancer earlier, ultimately improving patient outcomes and quality of life.
The 9th Annual ELLOK Conference featured high-level participation by the Minister of Health and other key government officials. International experts also contributed global perspectives on strengthening national cancer plans, expanding early screening programs, promoting digital transformation in healthcare, and reducing disparities in oncology treatment. Discussions were accompanied by presentations of new research, data-driven studies, and proposals on improving cancer care coordination at both national and European levels.
With policy discussions, roundtable sessions, and new research findings presented, the 9th Annual ELLOK Conference acted as a catalyst for innovative ideas and strengthened collaborations. Protavio’s presence at the conference underscored its focus on advancing diagnostic innovation, and by integrating research breakthroughs into everyday clinical practice, the company aims to accelerate progress in detecting early and accurately various cancer types. Dr. Alexopoulos’s contributions to the dialogue resonated strongly with the conference’s central message: that holistic collaboration among policymakers, industry representatives, scientists, and patient advocates is essential for more effective and equitable cancer care.